Philip Hall to Female
This is a "connection" page, showing publications Philip Hall has written about Female.
Connection Strength
0.171
-
Experience with dasatinib and nilotinib use in pregnancy. J Oncol Pharm Pract. 2018 Mar; 24(2):121-128.
Score: 0.030
-
Toxicities of gemcitabine in patients with severe hepatic dysfunction. Ann Pharmacother. 2010 Apr; 44(4):750-4.
Score: 0.018
-
Reducing anti-DT IgG concentrations to improve the efficacy of a diphtheria fusion protein. Anticancer Drugs. 2008 Nov; 19(10):1007-11.
Score: 0.017
-
Single-dose rasburicase 6 mg in the management of tumor lysis syndrome in adults. Pharmacotherapy. 2006 Jun; 26(6):806-12.
Score: 0.014
-
Treatment of acute myeloid leukemia during the second and third trimesters of pregnancy. Pharmacotherapy. 2005 Aug; 25(8):1134-40.
Score: 0.013
-
Antibody response to DT-GM, a novel fusion toxin consisting of a truncated diphtheria toxin (DT) linked to human granulocyte-macrophage colony stimulating factor (GM), during a phase I trial of patients with relapsed or refractory acute myeloid leukemia. Clin Immunol. 2001 Aug; 100(2):191-7.
Score: 0.010
-
DT388-GM-CSF, a novel fusion toxin consisting of a truncated diphtheria toxin fused to human granulocyte-macrophage colony-stimulating factor, prolongs host survival in a SCID mouse model of acute myeloid leukemia. Leukemia. 1999 Apr; 13(4):629-33.
Score: 0.009
-
Toxicology and pharmacokinetics of DT388-GM-CSF, a fusion toxin consisting of a truncated diphtheria toxin (DT388) linked to human granulocyte-macrophage colony-stimulating factor (GM-CSF) in C57BL/6 mice. Toxicol Appl Pharmacol. 1998 May; 150(1):91-7.
Score: 0.008
-
A phase I and pharmacokinetic study of high dose tamoxifen and weekly cisplatin in patients with metastatic melanoma. Cancer. 1997 Mar 01; 79(5):1037-43.
Score: 0.007
-
The influence of serum tumor necrosis factor-alpha and interleukin-6 concentrations on nonhematologic toxicity and hematologic recovery in patients with acute myelogenous leukemia. Exp Hematol. 1995 Nov; 23(12):1256-60.
Score: 0.007
-
Adjuvant therapy of node-negative breast cancer. Ann Pharmacother. 1995 Mar; 29(3):289-98.
Score: 0.006
-
Immunomodulation with intravenous immunoglobulin. Pharmacotherapy. 1993 Nov-Dec; 13(6):564-73.
Score: 0.006
-
Incidence of vancomycin-resistant enterococci (VRE) infection in high-risk febrile neutropenic patients colonized with VRE. Support Care Cancer. 2010 Feb; 19(2):231-7.
Score: 0.005
-
Interstitial diphtheria toxin-epidermal growth factor fusion protein therapy produces regressions of subcutaneous human glioblastoma multiforme tumors in athymic nude mice. Clin Cancer Res. 2005 Jan 01; 11(1):329-34.
Score: 0.003
-
Safety evaluation of DT388IL3, a diphtheria toxin/interleukin 3 fusion protein, in the cynomolgus monkey. Cancer Immunol Immunother. 2005 Aug; 54(8):799-806.
Score: 0.003
-
Toxicology and pharmacokinetics of DT388IL3, a fusion toxin consisting of a truncated diphtheria toxin (DT388) linked to human interleukin 3 (IL3), in cynomolgus monkeys. Leuk Lymphoma. 2004 Aug; 45(8):1647-56.
Score: 0.003
-
Expression and purification of the recombinant diphtheria fusion toxin DT388IL3 for phase I clinical trials. Protein Expr Purif. 2004 Jan; 33(1):123-33.
Score: 0.003
-
A phase II study of DT fusion protein denileukin diftitox in patients with fludarabine-refractory chronic lymphocytic leukemia. Clin Cancer Res. 2003 Sep 01; 9(10 Pt 1):3555-61.
Score: 0.003
-
Fentanyl-associated syndrome of inappropriate antidiuretic hormone secretion. Pharmacotherapy. 2002 Sep; 22(9):1188-92.
Score: 0.003
-
Phase I trial of a novel diphtheria toxin/granulocyte macrophage colony-stimulating factor fusion protein (DT388GMCSF) for refractory or relapsed acute myeloid leukemia. Clin Cancer Res. 2002 May; 8(5):1004-13.
Score: 0.003